Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/68519
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | High-dose docosahexaenoic acid supplementation of preterm infants: Respiratory and allergy outcomes |
Author: | Manley, B. Makrides, M. Collins, C. McPhee, A. Gibson, R. Ryan, P. Sullivan, T. Davis, P. |
Citation: | Pediatrics, 2011; 128(1):E71-E77 |
Publisher: | Amer Acad Pediatrics |
Issue Date: | 2011 |
ISSN: | 0031-4005 1098-4275 |
Statement of Responsibility: | Brett J. Manley, Maria Makrides, Carmel T. Collins, Andrew J. McPhee, Robert A. Gibson, Philip Ryan, Thomas R. Sullivan, and Peter G. Davis for the DINO Steering Committee |
Abstract: | BACKGROUND: Docosahexaenoic acid (DHA) has been associated with downregulation of inflammatory responses. OBJECTIVE: To report the effect of DHA supplementation on long-term atopic and respiratory outcomes in preterm infants. METHODS: This study is a multicenter, randomized controlled trial comparing the outcomes for preterm infants <33 weeks' gestation who consumed expressed breast milk from mothers taking either tuna oil (high-DHA diet) or soy oil (standard-DHA) capsules. Data collected included incidence of bronchopulmonary dysplasia (BPD) and parental reporting of atopic conditions over the first 18 months of life. RESULTS: Six hundred fifty-seven infants were enrolled (322 to high-DHA diet, 335 to standard), and 93.5% completed the 18-month follow-up. There was a reduction in BPD in boys (relative risk [RR]: 0.67 [95% confidence interval (CI): 0.47–0.96]; P = .03) and in all infants with a birth weight of <1250 g (RR: 0.75 [95% CI: 0.57–0.98]; P = .04). There was no effect on duration of respiratory support, admission length, or home oxygen requirement. There was a reduction in reported hay fever in all infants in the high-DHA group at either 12 or 18 months (RR: 0.41 [95% CI: 0.18–0.91]; P = .03) and at either 12 or 18 months in boys (RR: 0.15 [0.03–0.64]; P = .01). There was no effect on asthma, eczema, or food allergy. CONCLUSIONS: DHA supplementation for infants of <33 weeks' gestation reduced the incidence of BPD in boys and in all infants with a birth weight of <1250 g and reduced the incidence of reported hay fever in boys at either 12 or 18 months. |
Keywords: | docosahexaenoic acid allergy respiratory premature infants |
Rights: | Copyright © 2011 by the American Academy of Pediatrics |
DOI: | 10.1542/peds.2010-2405 |
Published version: | http://dx.doi.org/10.1542/peds.2010-2405 |
Appears in Collections: | Aurora harvest Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.